Tetanus immune globulin (human) - Biologic Drug Details

✉ Email this page to a colleague

Summary for tetanus immune globulin (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for tetanus immune globulin (human)

Recent Clinical Trials for tetanus immune globulin (human)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Grifols Therapeutics LLC	Phase 4
Grifols Therapeutics Inc.	Phase 4

See all tetanus immune globulin (human) clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tetanus immune globulin (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tetanus immune globulin (human) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for tetanus immune globulin (human) Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Tetanus Immune Globulin (Human)

Last updated: February 17, 2026

Overview: Tetanus immune globulin (human) (TIG) is a human-derived immunoglobulin used to prevent or treat tetanus infections, primarily via passive immunization. The market landscape has evolved due to regulatory standards, supply chain considerations, and advancements in immunoglobulin manufacturing.

Market Size and Growth Drivers

Global Market Valuation (2022): Approximately $200 million, with a compounded annual growth rate (CAGR) projected at 4-5% through 2028. Market figures derive from persistence in tetanus prophylaxis, especially in developing regions where vaccination coverage remains inconsistent.
Incidence of Tetanus: Estimated 1-2 cases per million in developed nations, but higher in low-income areas due to vaccination gaps. Regions with low immunization rates see steadier demand.
Vaccination Policies: Updated CDC and WHO guidelines emphasize immunoglobulin administration post-exposure for unvaccinated or immunocompromised individuals, maintaining demand stability in healthcare systems.

Market Dynamics

Supply Chain Challenges: Limited plasma donors and manufacturing capacity constrain supply. Plasma sourcing policies and risk mitigation (e.g., pathogen reduction procedures) increase production costs.
Regulatory Landscape: Stringent FDA and EMA regulations govern production, importation, and quality standards. Changes influence market entry and pricing structures.
Pricing Trends: Prices vary by region; anticipated to increase slightly due to manufacturing costs and supply constraints. In the U.S., average wholesale prices hover around $1,000–$1,200 per vial.
Competitive Landscape:
- Predominantly sourced from pooled human plasma.
- Few approved alternatives; tetanus immune globulin remains the standard for passive immunity.
- Emerging biotechnological approaches, such as monoclonal antibodies, are in early-stage development but face regulatory hurdles.

Financial Trajectory and Investment Outlook

Indicator	2022	2028 (Projected)	Comments
Revenue	~$200 million	~$250–275 million	Growth driven by increasing prophylaxis needs in vulnerable populations
Manufacturing Costs	Steady increase	Slight increase	Costs linked to plasma collection, pathogen safety, and compliance
R&D Investment	Limited	Potential increase	Focus on improving yield efficiency, alternate sources, and synthetic options
Market Penetration	Saturated in developed countries; expanding in developing regions	Slight expansion	Driven by vaccination campaigns, healthcare infrastructure improvements

Emerging Trends:
- Countries improve access to contracted plasma collection programs and infrastructure.
- Increase in targeted prophylaxis in high-risk populations.
- Potential impact of novel monoclonal antibody-based products, though these are years from commercialization.
Future Risks:
- Plasma supply shortages due to donor variability.
- Regulatory delays or tightening standards.
- Competition from recombinant or synthetic alternatives.

Regulatory and Policy Factors

Regulatory agencies require detailed characterization of plasma-derived products.
WHO’s prequalification program influences procurement in low- and middle-income countries.
US and EU regulations favor strict pathogen safety and consistency measures, affecting production costs and market entry.

Summary of Key Data

Annual Revenue (2022): ~$200 million.
CAGR (2023–2028): 4–5%.
Pricing: $1,000–$1,200 per vial.
Global Demand: Growing in low-income countries due to vaccination gaps and lack of alternative prophylaxis.
Supply Constraints: Limited plasma donors, high manufacturing costs, complex quality controls.

Key Takeaways

The TIG market remains stable due to essential clinical use, but constrained by supply and regulatory hurdles.
Market growth depends heavily on improving plasma sourcing, expanding access in underserved regions, and managing costs.
Innovations are likely to emerge from synthetic or monoclonal antibody-based therapies, potentially disrupting traditional plasma-based products long-term.
Price increases are expected but limited by reimbursement policies and market competition.
Geopolitical factors and public health initiatives will influence regional demand dynamics.

FAQs

1. What factors limit the growth of the tetanus immune globulin market?
Supply chain limitations, plasma donor shortages, high manufacturing costs, and regulatory constraints restrict growth. These factors maintain market volume despite steady demand.

2. Are there efforts to develop alternatives to plasma-derived TIG?
Yes, early-stage research explores monoclonal antibodies and recombinant immunoglobulins, but these are not yet commercially available or approved.

3. How do regional vaccination policies impact the TIG market?
In regions with low vaccination rates, demand for TIG increases due to reliance on passive immunization post-exposure, especially where immunization coverage is incomplete.

4. What is the role of government regulations in shaping market financials?
Regulatory standards influence production costs, supply chain stability, and pricing. Stringent safety and quality guidelines increase operational costs but ensure market integrity.

5. How might the market evolve over the next five years?
Demand will remain steady, driven by persistent tetanus prevalence in underserved areas. Supply and cost pressures will persist, but technological innovations could introduce new therapies that disrupt the traditional market landscape.

Sources:
[1] MarketsandMarkets, "Immunoglobulin Market," 2022
[2] CDC, "Tetanus Vaccine and TIG Usage," 2022
[3] Global Data, "Biologics Market Trends," 2022

More… ↓

⤷ Start Trial